Navigation Links
Ceragenix Announces Results from Phase IV Study of EpiCeram Meet,All Primary and Secondary Endpoints

DENVER--(BUSINESS WIRE)--Apr 24, 2007 - Ceragenix Pharmaceuticals Inc. (OTCBB:CGXP) today announced positive results from its post-clearance marketing study comparing EpiCeram's(TM) efficacy to that of Cutivate(R) cream, a mid-strength topical steroid in the treatment of moderate-to-severe atopic dermatitis (AD).

The study, which took place at five centers, consisted of 113 pediatric patients, with 59 patients receiving treatment with Cutivate(R) and 54 patients receiving treatment with EpiCeram(TM). After 28 days of treatment, the study demonstrated that: -0-

       Both EpiCeram(TM) and Cutivate(R) produced significant

       improvement in patients' conditions after 28 days of treatment;


       There were no statistically significant differences between the

       groups treated with EpiCeram(TM) compared to those treated with

       Cutivate(R) as measured by the SCORAD index at Day 28 (the

       primary outcome measure) or in the percentage of patients

       assessed to be "clear or almost clear" by physician assessment

       at Day 28 (a secondary outcome measure).


       Both EpiCeram(TM) and Cutivate(R) produced significant relief

       from itching (pruritus) and improvement in sleep habits after

       28 days of treatment and that there was no statistically

       significant difference between the two treatments in these

       measures at this time point (both secondary outcome measures).

"The data from this study demonstrate that EpiCeram(TM) is effective and offers both the clinician and parents a new approach for treating atopic dermatitis without the risks often associated with long-term use of topical steroids or immunosuppressants," said Lawrence Charles Parish, M.D., Clinical Professor of Dermatology and Cutaneous Biology at Jefferson Medical College of Thomas Jefferson University in Philadelphia, one of the study's principal investigators.

Atopi
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Ceragenix Compound Shows Promise for Treating Lethal Cystic Fibrosis Infections
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:5/26/2015)... , May 26, 2015 ... business solutions, today announced the results of an ... perform day-to-day activities. 759 therapists, practice owners and ... a widespread industry need for technology and services ... to the survey findings, Clinicient published a free ...
(Date:5/26/2015)... , May 26, 2015  PAREXEL International Corporation (NASDAQ: ... presenting at the Goldman Sachs Healthcare Conference in Palos ... Chief Executive Officer, will be making a presentation on ... on Tuesday, June 9, 2015. A live ... "Investors" section of PAREXEL,s website at www.PAREXEL.com ...
(Date:5/26/2015)... TAMPA, Fla. , May 26, 2015 /PRNewswire/ ... wholly-owned subsidiary, Pharmacy Value Management Solutions, Inc. ("PVMS"), ... today that effective immediately Mr. Matt Capps ... Senior Public Relations Consultant to the Company,s Community ... financial position in Advanzeon.  This engagement provides for ...
Breaking Medicine Technology:Survey: Half of Physical Therapists Underbill For Their Services 2PAREXEL International To Present At Goldman Sachs Healthcare Conference 2Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 2Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 3Advanzeon Solutions, Inc. And Its Wholly-Owned Subsidiary, Pharmacy Value Management Solutions, Inc., Welcome Major League Baseball Great Matt Capps As Senior Public Relations Consultant 4
... , , NEW YORK, Dec. 21 ... a leading provider of pre-disease adult stem cell collection, processing ... to VSEL(TM) technology that uses very small embryonic-like stem cells ... two oral presentations at the prestigious American Society of Hematology ...
... , PRINCETON, N.J., Dec. 21 Soligenix, ... formerly known as DOR BioPharma, Inc., a late-stage biotechnology ... 1/2 clinical trial evaluating SGX201, a time-release formulation of ... acute radiation enteritis. This study will be supported in ...
Cached Medicine Technology:The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 2The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 3The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 4The Impact of Very Small Embryonic-Like Stem Cells in Regenerative Medicine is Highlighted by Five Posters and Two Oral Presentations at the 2009 American Society of Hematology Annual Meeting 5Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 2Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 3Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 4Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 5Soligenix Announces Initiation of a Phase 1/2 Clinical Trial of SGX201 for the Prevention of Acute Radiation Enteritis 6
(Date:5/27/2015)... One of America's most cherished actors, James Earl Jones, ... takes a look at the topic of atrial fibrillation. ... heart rhythm. Those who suffer from atrial fibrillation have ... quickly. , This new segment will take a look ... inform viewers about possible signs that commonly indicate the ...
(Date:5/27/2015)... 2015 Hands On HealthCare Massage ... offering Eco-fin Hand Treatments to spa party guests, effective ... wax alternative. It is a healthy, nourishing hand/foot treatment ... and pure essential oils. No petroleum, artificial dyes, or ... treatments for our mobile spa party services ...
(Date:5/27/2015)... (PRWEB) May 27, 2015 The Advanced Fertility ... is open for business to better serve the needs ... the Jefferson Park neighborhood on the Northwest side of the ... Appointments can be arranged by calling the Chicago office at ... the Advanced Fertility Center of Chicago. The other 2 ...
(Date:5/26/2015)... 27, 2015 Local dentist Abid Paghdiwala ... restful night’s sleep. Dr. Paghdiwala of Pearl Dental Arts ... (AADSM) member. AADSM is the leading national organization for ... oral appliance therapy, an effective alternative treatment to the ... , “Sleeping with a CPAP machine, which includes ...
(Date:5/26/2015)... OAK BROOK, Ill. (PRWEB) May 26, 2015 ... may be an early marker of specific types of ... of a new study published in the journal Radiology. ... Federica Agosta, M.D., Ph.D., co-author of the study conducted ... in Milan, Italy. “However, white matter damage has a ...
Breaking Medicine News(10 mins):Health News:Long Island's Massage and Spa Of Commack Announces A Change To Their Spa Party Menu Of Services 2Health News:Long Island's Massage and Spa Of Commack Announces A Change To Their Spa Party Menu Of Services 3Health News:The Advanced Fertility Center of Chicago Opens a New Fertility Office Location in Chicago 2Health News:Philadelphia sleep apnea dentist now offers oral appliances to treat snoring 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 2Health News:RSNA: Imaging Test May Identify Biomarker of Alzheimer’s Disease 3
... and Emerging Targeted Therapies Such As AstraZeneca,s Iressa and ... 2013, According to a New Report from Decision Resources ... the world,s leading research and advisory firms focusing on ... cancer drug market in China will more than double ...
... oximetry data may help identify difficult to diagnose disease ... Somanetics Corporation (Nasdaq: SMTS ) announced today ... and presentations at the Pediatric Academic Societies (PAS) annual ... The studies focused on early applications of the technology ...
... -- Style maven and trend setter Kim Kardashian ... "Fit In Your Jeans By Friday." Produced and distributed by ... to have you crunching, lunging and wriggling into the latest ... 9th, 2009."Women need a realistic body image. My program is ...
... N.C., May 6 RIEMSER ... implant and wound healing products, has announced an upcoming ... on Friday, June 5th from 8:00 am to 1:30 ... preservation, information on bone grafting materials and methods, and ...
... Endo Pharmaceuticals (Nasdaq: ENDP ) announced today that ... Lynch 2009 Health Care Conference on Wednesday, May 13, 2009 ... Chief Executive Officer of Endo, will review the company,s products ... be accessed from Endo,s website at www.endo.com ...
... NEW YORK, May 6 CorMatrix Cardiovascular, Inc., ... unique extracellular matrix (ECM(TM)) biomaterial devices that harness ... tissue, today announced that Robert G. Matheny, M.D., ... the company,s ECM Technology(TM) at the 2009 Advanced ...
Cached Medicine News:Health News:Chinese Non-Small-Cell Lung Cancer Drug Market Will More Than Double by 2013 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 2Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 3Health News:25 Clinical Abstracts at National Conference Spotlight Clinical Utility of Somanetics INVOS System in Neonates 4Health News:Kim Kardashian Says Real Women Keep Their Curves With 'Fit In Your Jeans By Friday' 2Health News:RIEMSER Announces Upcoming Scottsdale Bone Grafting Workshop 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 2Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 3Health News:Endo to Present at Bank of America and Merrill Lynch 2009 Health Care Conference 4Health News:CorMatrix Cardiovascular to Present on its ECM Technology(TM) at the Annual Advanced Cardiac Techniques in Surgery (ACTS) Symposium in New York, N.Y. 2
Long handle occluders are approximately 9 inches long....
Manual Lensmeter....
Lightweight, cordless lensmeter....
Lightweight, cordless lensmeter....
Medicine Products: